07/20/2026
Anapharm Bioanalytics GLP Certificate Renewal
Barcelona, July 2026 – Anapharm Bioanalytics is pleased to announce the successful renewal of its Good Laboratory Practice (GLP) certification following the latest inspection conducted by local authority, Generalitat de Catalunya, in June 2026.
Anapharm has operated under GLP compliance since 2003 and the renewed certificate is valid until June 2028. The recent on-site inspection concluded with no observations and no findings, an outstanding result that reflects the robustness of the company's quality system.
While these inspections take place every two years, achieving an inspection outcome with no observations or findings should never be taken for granted. This is the result of many years of continuous improvement, well-established processes, and the daily commitment of our teams to maintaining the highest quality standards.
For Anapharm, this achievement goes beyond regulatory compliance. Sponsors experience the scientific expertise of our teams, our dedicated project management, and our responsiveness throughout a study. However, inspections such as this provide independent confirmation that the systems and processes supporting that work are robust, giving clients additional confidence in the quality and reliability of the data generated for their development programs.
Anapharm would like to thank all employees whose daily dedication, professionalism and attention to detail contributed to this achievement.
About Anapharm Bioanalytics
Anapharm Bioanalytics is a bioanalytical CRO with +20 years’ experience, specialized in supporting pharmaceutical and biotechnology companies throughout drug development, from early discovery, through GLP tox studies and Phase I–III clinical trials. The company provides bioanalytical support for peptides, small molecules and biologics, covering PK, ADA and biomarkers testing, operating under GLP and GCP-compliant quality systems to deliver reliable and high-quality data to clients worldwide.
Speak with a bioanalytical specialist today.
MORE NEWS
ADA for a small recombinant protein: development and troubleshooting
ADA assay development is technically complex and often requires iterative optimisation to overcome challenges such as drug interference, matrix effects and non-specific binding. The aim of this poster, is to present the troubleshooting process followed during the development of an assay for the detection of ADA against a recombinant protein of 24kDa.
Challenges in the development of a method for the detection of Free Testosterone
In the present study, we aim to optimize a competitive enzyme-linked immunosorbent assay (ELISA) for the measurement of free testosterone within a regulated pharmacokinetic (PK) framework, with the objective of achieving a sensitivity in the range of 0.2–0.6 pg/mL. This poster presents key challenges encountered during method development and validation, and discusses the strategies implemented to overcome them.
Computerized Systems Validation in Bioanalysis: Regulatory Requirements and How It Works in Practice
In this blog post, we will take a closer look at the importance of CSV in a GLP & GCP environment and explore some of the key computerized systems that play a critical role in supporting our laboratory operations and ensuring data quality.